Vaccine

The Philadelphia Inquirer published an article regarding the development of a vaccine for Lyme disease, October 2013. The article is titled, “It’s Time to Develop a Vaccine for Lyme Disease, Doctor Says” by Ilene Raymond Rush.  We are providing a repsonse to that article by Stephen A. Sheller, founding partner of Sheller, P.C., a national whistleblower, plaintiff’s product liability, personal injury class action law firm based in Philadelphia. His book including his work on Lyme Disease, A Nation Betrayed, is soon to be released. Click here for the article in Philadelphia Inquirer    Click here for the Op-Ed

On January 22, 2002 in Bethesda, MD., the LDA was able to get a private meeting with the FDA on the vaccine issue, despite reluctance by the FDA to grant the meeting. Congressman Chris Smith helped facilitate the setup of this meeting. On February 25, 2002, a month after meeting with FDA, LDA received written answers to its questions from FDA and, also, learned that Glaxo SmithKline had quietly pulled Lymerix from the market, citing "poor sales." CLICK HERE FOR THE RESPONSE

This is an FDA powerpoint by Robert Ball, M.D., M.P.H., Sc.M., on the Lymerix Vaccine, LYMErix® Safety Data Reported to the Vaccine Adverse Event Reporting System (VAERS), January 31, 2001. Robert Ball, M.D., M.P.H., Sc.M., Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Rockville, MD  CLICK HERE FOR THE POWERPOINT

This is a piece on the Lymerix Vaccine controversy, written by Patricia V. Smith, President, Lyme Disease Association, Inc., which appeared in the Lyme Times. The LYMErix™ Story: FDA Approval to Market Withdrawal ─ Learning from History Click here to read article

REMARKS OF PAT SMITH, PRESIDENT, LYME DISEASE ASSOCIATION, INC. BEFORE THE VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE, MAY 21, 2002. Why more adverse events were seen after the vaccine reached the market: 
    People receiving Lymerix after product launch lived in Lyme-endemic areas.